Aclipse Therapeutics Has Partnered With Mayo Clinic
The organizations will conduct a clinical trial for a potential new gastroparesis treatment.
Updated on Sept. 24, 2026 in Diabetes
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare chronic diseases?
Aclipse Therapeutics has entered into a clinical research agreement with the Mayo Clinic to launch a Phase 2 trial for the drug M107. The study aims to evaluate the treatment for patients with idiopathic gastroparesis.
Why it matters
Currently, there are no approved drugs designed to fundamentally treat gastroparesis, a condition marked by delayed gastric emptying. M107, based on the active ingredient lobeglitazone, seeks to address the underlying causes of the disorder.
The clinical trial will be conducted across 3 Mayo Clinic campuses located in Rochester, Minnesota; Phoenix, Arizona; and Jacksonville, Florida. M107 utilizes lobeglitazone to promote anti-inflammatory M2 macrophage expression.
The players
Aclipse Therapeutics
Aclipse Therapeutics is the global licensing partner of the South Korean firm CKD.
Mayo Clinic
Mayo Clinic is a prominent non-profit American academic medical center focused on integrated health care, education, and research.
CKD
CKD is a South Korean pharmaceutical company that signed a global licensing agreement with Aclipse in 2023.
The details
The LOGAST trial will be an investigator-initiated study supported by research funding from Aclipse Therapeutics. The drug works by reducing pro-inflammatory M1 macrophages while promoting the anti-inflammatory M2 variety.
Timeline
CKD and Aclipse signed a global licensing agreement in 2023.
Patient enrollment for the clinical trial is expected to begin in the first quarter of 2026.
The Big Picture
This collaboration fits within the ongoing expansion of the Mayo Clinic's idiopathic gastroparesis research initiatives. The partnership marks a shift toward testing novel oral therapies for a condition that has historically lacked disease-modifying treatments.
The trial offers hope for individuals suffering from chronic delayed gastric emptying, for which no fundamental drug therapies currently exist. Participants meeting the study criteria may gain early access to the investigational drug M107.
The takeaway
The initiation of the LOGAST trial represents a significant step in the effort to find a pharmacological solution for gastroparesis. Patients affected by the condition should consult with their healthcare providers regarding eligibility for upcoming clinical trials.
What happens next
Patient enrollment for the LOGAST clinical trial is scheduled to begin in the first quarter of 2026.
Further reading
For more information on current treatment landscape and research, visit the Diabetes section.
Source note: This article includes information reported by Pulse.
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare chronic diseases?
